期刊文献+

ACEI联合ARB在糖尿病肾脏病治疗中的应用 被引量:4

下载PDF
导出
摘要 糖尿病肾脏病(DKD)是糖尿病最常见的微血管并发症之一,约占1型糖尿病发病率的35%~40%,约占2型糖尿病发病率的28.3%,而90%~95%的糖尿病患者为2型糖尿病,因而半数以上的DKD由2型糖尿病引起[1]。大量临床试验已证实,血管紧张素转换酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB)在DKD患者中除了具有降血压作用外,还具有显著肾脏保护作用.
作者 胡婷 任伟
机构地区 重庆医科大学
出处 《现代医药卫生》 2016年第10期1517-1520,共4页 Journal of Modern Medicine & Health
  • 相关文献

参考文献24

  • 1Ruddy MC. Angiotensin Ⅱ receptor blockade in diabetic nephropathy[J]. Am J Hypertens, 2002,15 (5) :468-471.
  • 2Americal Diabetes Association. Diabetic nephropathy[J]. Diabetes Care, 2003,25 ( Suppl 1 ) : 94-98.Luther JM, Gainer JV, Murphey LJ. Angiotensin Ⅱ induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism[J]. Hypertension, 2006,48 (6) : 1050-1057.
  • 3Luther JM, Gainer JV, Murphey LJ. Angiotensin Ⅱ induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism[J]. Hypertension, 2006,48 (6) : 1050-1057.
  • 4徐茜,汤正义,杨洋,田秀丽,黄佳佳,王卫庆,宁光.局部肾素-血管紧张素-醛固酮系统与糖尿病肾病的治疗[J].世界临床药物,2008,29(11):647-650. 被引量:7
  • 5Wolf G, Ziyadeh FN. The role of angiotensin Ⅱ in diabetic nephropathy : emphasis on nonhemodynamic mechanisms[J]. Am J Kidney Dis, 1997, 29( 1 ) : 153-163.
  • 6Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy[J]. Proc Natl Acad Sci USA,2000, 97 (14),7667-7669.
  • 7Song JH, Cha SH, Lee HJ, et al. Effect of low-dose dual blockade of reninangiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease[J]. Nephrol Dial Transplant, 2006,21 (3) :683-689.
  • 8秦会娟,温玉洁,刘陶文.血管紧张素转化酶抑制剂联合血管紧张素Ⅱ受体拮抗剂应用于糖尿病肾病的研究进展[J].医学综述,2012,18(1):124-126. 被引量:16
  • 9Stratton IM,Cull CA,Adler AI,et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes:a prospective observational study ( UKPDS 75 ) [J]. Diabetologia, 2006, 49(8) : 1761-1769.
  • 10Jacobsen P,Andersen S,Rossing K,et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy[J]. Nephrol Dial Transplant, 2002,17 (6) : 1091-1024.

二级参考文献29

  • 1Ambroisine ML, Milliez P, Nehme J, et al. Aldosterone and anti-al- dosterone effects in cardiovascular diseases and diabetic nephropa- thy[J]. Diabetes Metab,2004,30(4) :311-318.
  • 2Brown NJ. Aldosterone and vascular inflammation [ J ]. Hyperten- sion ,2008,51 ( 2 ) : 161-167.
  • 3Luther JM, Gainer JV, Murphey LJ. Angiotensin Ⅱ induces inter- leukin-6 in humans through a mineralocorticoid receptor-dependent mechanism[ J]. Hypertension ,2006,48 ( 6 ) : 1050-1057.
  • 4Ferrari P. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease [ J ]. Neph- rology,2007,12( 1 ) :81-89.
  • 5Gasparo MDE, Levens NR. Pharmacology of angiotensin II receptor in the kidney [ J ]. Kidney Int, 1994,46 (6) : 1486-1491.
  • 6Remuzzi A, Perticucci E, Reggenenti P, et al. Angiotensin conver- ting enzyme inhibition improve glomarular size selecti-vity in IgA nephropathy [ J ]. Kidney Int, 1991,39 ( 6 ) : 1267-1273.
  • 7Woo KT, Lau YK, Wong KS, et al. ACE][/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephri- tis[ J]. Kidney Int,2000,58 ( 6 ) :2485-2491.
  • 8Nakao N,Yoshimura A, Morita H, et al. Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease( COOPER ATE) :a random- ised controlled trial[ J ]. Lancet,2003,361 (9352) : 117-124.
  • 9Krum H,Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure:re- sults from Val-HeFT[ J]. Eur J HeartFail,2004,6(7) :937.
  • 10McMurray J J, Ostergren J, Swedberg K,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial [ J ]. Lancet,2003,362 (9386) : 767 -771.

共引文献19

同被引文献16

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部